<DOC>
	<DOCNO>NCT00920309</DOCNO>
	<brief_summary>Currently approve use rapamycin ( sirolimus ) immunosuppression renal transplantation . This trial design determine whether rapamycin safe effective treatment patient polycystic kidney disease ( ADPKD ) . Patients follow volumetric magnetic resonance imaging ( MRI ) observe change kidney ( cyst ) size . Blood urine sample also collect evaluate change biomarkers treatment .</brief_summary>
	<brief_title>Rapamycin Treatment Autosomal Dominant Polycystic Kidney Disease ( ADPKD ) : The Role Biomarkers Predicting Response Therapy</brief_title>
	<detailed_description>This 2 year , open label trial evaluate role rapamycin treatment ADPKD . Patients randomize 2:1 rapamycin arm standard therapy . The dose rapamycin adjust patient obtain 24 trough level 4-6ng/ml . There volumetric MRI measurement start end treatment period . Patients monitor every 4 month throughout study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>adult ADPKD patient age 1870 combined kidney volume &gt; 1200 ml estimate creatinine clearance &gt; 60 ml/min absence implant ferromagnetic object Age &gt; 70 uncontrolled hyperlipidemia Proteinuria &gt; 500 mg/day unstable cerebral aneurysm active coronary artery disease diagnosis another systemic condition affect kidney function ( ie : diabetes , hepatitis B C , HIV ) diagnosis cancer skin cancer pregnancy lactation presence implant ferromagnetic object</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>rapamycin</keyword>
	<keyword>ADPKD</keyword>
</DOC>